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1. Introduction
For the last three decades the intensive research
studies and developments of polymer systems for
controlled release of pharmaceuticals have been
carried out [1–3]. At curative dose the prolonged
delivery of drugs from the systems into organism
permits to eliminate the shortcomings in peroral,
injectable, aerosol, and the other traditional meth-
ods of drug administration. Among those shortcom-
ings hypertoxicity, instability, pulsative character
of rate delivery, ineffective expenditure of drugs
should be pointed out. Alternatively, applications
of therapeutical polymer systems provide orderly
and purposefully the deliverance for an optimal
dose of agent that is very important at therapy of
acute or chronic diseases [4]. At treatment of car-
diovascular and other diseases one of the perspec-
tive classes of drugs is the class of inhibitors of cell
proliferation (ICP). In particular, pharmaceuticals
on the base of ICP are widely used for preventing
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Abstract. Novel biodegradable microspheres on the base of poly(3-hydroxybutyrate) (PHB) designed for controlled
release of antithrombotic drug, namely dipyridamole (DPD), have been kinetically studied. The profiles of release from the
microspheres with different diameters 4, 9, 63, and 92 μm present the progression of nonlinear and linear stages. Diffusion-
kinetic equation describing both linear (PHB hydrolysis) and nonlinear (diffusion) stages of the DPD release profiles from
the spherical subjects has been written down as the sum of two terms: desorption from the homogeneous sphere in accor-
dance with diffusion mechanism and the zero-order release. In contrast to the diffusivity dependence on microsphere size,
the constant characteristics (k) of linearity are scarcely affected by the diameter of PHB microparticles. The view of the
kinetic profiles as well as the low rate of DPD release are in satisfactory agreement with kinetics of weight loss measured
in vitro for the PHB films. Taking into account kinetic results, we suppose that the degradation of both films and PHB
microspheres is responsible for the linear stage of DPD release profiles. In the nearest future, combination of biodegradable
PHB and DPD as a representative of proliferation cell inhibitors will give possibility to elaborate the novel injectable ther-
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DOI: 10.3144/expresspolymlett.2007.110the spread of restenosis after operations in cardio-
vascular surgery [5, 6]. In this relation, it has been
recently shown that a wide-spread antithrombotic
drug dipyridamole (DPD) inhibits effectively the
cell proliferation, but the DPD advantages the
minority of negative by-effects [7, 8] in contradis-
tinction to most of ICP. In accordance with this
argument DPD has been picked over as the effector
for designing polymer therapeutic system for con-
trolled drug delivery. Quit recently Zhu and
coworkers [9] have designed the DPD controlled
release polymer system on the base of micros-
pheres composed of polylactide – polyglicolide
copolymers (PLGA). They have clearly shown that
DPD release includes two stages: the diffusion
stage and the subsequent stage of hydrolytic degra-
dation of PLGA. It is worth to note that the use of
implants consisting of polylactides, polyglicolides
and their copolymers is not without a number of
sequelae related with the chronic inflammatory
reactions in tissue [10–14].
Instead of PLGA applications, we propose alterna-
tively to use bacterial poly(3-hydroxybutyrate)
(PHB) [15]. Recently PHB and its copolymers are a
focus of attention as biodegradable and biocompat-
ible materials for biomedicine. The combination of
physical and biological properties promote the use
of this polymer for design and elaboration of differ-
ent medical devices such as surgical sutures, repair
patches, vascular prostheses, stents, periodontal
membranes, orthopaedic implants, wound dress-
ings etc. [16]. Besides, the ability of PHB to encap-
sulation and further release of drugs permits the use
of PHB to design novel therapeutic systems [15].
Taking into account the above arguments, the
objects of this paper are the production of PHB
microspheres loaded with the DPD as well as the
study of kinetic profile of the drug release in car-
diovascular therapy. In the nearest future, combina-
tion of biodegradable PHB and DPD as a represen-
tative of proliferation cell inhibitors will give
possibility to design an injectable therapeutic sys-
tem for a local, long-term, antiproliferative action.
2. Materials and methods
2.1. PHB production
The PHB strain used in this work (Azotobacter
chroococcum 7B) was capable of synthesizing PHB
in an amount of up to 80% on the dry weight basis
of the cells. A collection of strains of the genus
Azotobacter were maintained on Ashbey’s medium.
To achieve cellular PHB hyperproduction, the cul-
ture of the Azotobacter strain was grown on
Burke’s medium in excess of content of the carbon
source [17]. The process of isolation and purifica-
tion from the biomass of A. chroococcum 7B
included the following stages: dissolution of PHB
in chloroform by shaking at 37°C for 12 h, separa-
tion of the PHB solution from the cell residue by
filtration, isolation of the PHB by isopropanol pre-
cipitation, and repeated its dissolution in chloro-
form followed by isopropanol precipitation and
drying at 60°C. The MW of the polymer was deter-
mined by viscosimetry. Measurements of viscosity
in the PHB – chloroform solutions were performed
at 30°C. The MW was calculated using the Mark-
Houwink-Kuhn equation [η] = 7.7·10–5·M0.82 [18].
The chemical structure of PHB, the type of its crys-
tal lattice, and its crystallinity (0.74) were previ-
ously determined using the methods of differential
scanning calorimetry, IR Fourier spectroscopy, and
crystal X-ray structure analysis [19].
2.2. Microsphere preparation and
characterization
Dipyridamole-incorporated PHB microspheres
were prepared using an oil-in-water emulsion
method [9]. PHB polymer with molecular weight
(MW) of 485 kDa was used for microspheres
preparation. DPD and PHB in proportions of 1:4
were dissolved in 8 ml of chloroform. The solution
was added drop-wise to 300 ml of PVA solution
(0.4–1.2% w/v) while stirred. The mixture was
homogenized for 2 h at 600–2000 rpm using an
overhead stirrer RZR 2021 (Heidolph, Germany) or
at 20 000 using a homogenizer SilentCruisher M
(Heidolph, Germany). After complete chloroform
evaporation the produced solid microspheres were
divided by glass filter with various pore sizes. The
final product was obtained by centrifugation
(5702 R centrifuge, Eppendorf, Germany), washing
with distilled water. The centrifugation and wash-
ing processes were repeated at least five times to
completely remove PVA and DPD adsorbed onto
the microspheres surface. Then the microspheres
were dried in thermostat at 60°C and gently pow-
dered. Encapsulation efficiency of microspheres
was calculated from the ratio of the encapsulated
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amount used for preparation.
For the microspheres with the highest diameter
(group 4) we duplicated the concentration of DPD
in order to enhance the rate of release. (The rate of
release is decreased with the increase of sphere
diameter). The concentration increase was required
for the sake of adjustment of all kinetic profiles
including the largest microspheres in the same time
scale (x-axis). The amount of loaded DPD was
determined by dissolving the microspheres in chlo-
roform followed by spectrophotometric analysis
with UV-spectrophotometer DU-650 (Beckman
Coulter, USA) at maximums of DPD absorption
(293 and 415 nm). The preparation of PHB films
for loss of polymer mass presented in Figure 4 has
been described in our preliminary paper [15].
2.3. In vitro release
Controlled release of DPD from PHB microspheres
was carried out at conditions in vitro: in phosphate-
buffered saline (pH 7.4) at 37°C. Eight lots of each
group of about 5 mg of DPD-loaded PHB micros-
pheres were used as drug depot. 4 ml of release
medium (phosphate-buffered saline, pH 7.4) was
added to each drug depot in the vial to maintain
sink conditions. The mixture was agitated at 50 rpm
at magnetic stirrer MS-01 (Elmi, Latvia) in a ther-
mostat TC-1/20 (Russia) at 37°C. At specific time
points, release medium was sampled completely by
centrifugation of mixture at 14 000 rpm (5702 R
centrifuge, Eppendorf, Germany) and assayed for
DPD using the spectroscopic method. The release
kinetics was then determined. The removed release
medium was replaced with an equal volume of
fresh medium after each sampling and was added to
deposited microspheres. Residual content of DPD
in microspheres was also measured by spectropho-
tometric technique. The conditions of experiment
(stirring rate, volume and concentration of working
solutions) for obtaining of DPD-loaded PHB
microspheres with different diameter are collected
in Table 1. From this table we can see that the stir-
ring rate is a dominating factor affecting the sphere
diameter. The weight loss of polymer films was
determined by drying and weighting of the samples
after their exposition in the buffer as it was
described in [15].
3. Results and discussion
As a drug vehicle of DPD, we have used the
microspheres produced from PHB solution by the
oil-in-water emulsion method described in Experi-
mental part. The pioneer work devoted to PHB
microsphere preparation have been presented in
[18]. Figure 1 presents a typical microphotograph
of spherical samples with diameter 63 µm loaded
by DPD. As can be seen in this figure, the PHB
subjects have the spherical form without visible
defects. They are adequately homogeneous and do
not have visible inclusions or voids. Besides, the
yellow DPD has slightly colored the interior of the
microspheres; therefore, as well as Kassab et al.
[20], we assume a uniform distribution of the drug
throughout the volume of a microsphere.
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Table 1. The conditions for producing PHB microspheres of different diameter loaded with definite content of DPD
*Averaged values for ten samples with standard deviation
Group
#
Mass of DPD in 
working solution 
[mg]
Mass of PHB in
working solution
[mg]
PVA 
concentration
[% (w/w)]
Stirring 
rate 
[rpm]
Diameter of 
microspheres 
mkm ± SD
DPD content in 
PHB microspheres
[% (w/w)]*
1 24 96 0.8 2000 03.6 ± 2.4 04.8 ± 0.4
2 24 96 0.6 1000 18.7 ± 2.9 05.2 ± 0.4
3 24 96 0.4 0600 62.7 ± 6.6 04.9 ± 0.4
4 47 1000 0.6 0500 91.7 ± 15.4 11.0 ± 0.5
Figure 1. Microphotographs of PHB microspheres loaded
by DPD with diameters 63 µmThe kinetic profiles of DPD release into phosphate
buffer for the microspheres with different diame-
ters are presented in Figure 2. The curves 3 and 4
referring to the series with the bigger diameters 63
and 92 µm, respectively, have two distinctive
ranges: the initial range where fast release is
observed and the following one where the constant
rate is exhibited for a sufficiently long time of
release (several hundreds of hours). For the micros-
pheres with a relatively small diameter (19 µm,
curve 2), we may also point out a small linear part
of the drug release curve for 6–21 h interval, but for
the smallest samples (diameter is as small as 4 µm,
curve 1) the linear range is practically missing.
The similar profiles of drug release had been
observed and have been well described for the
microspheres on the base of PLGA and loaded by
5-fluorouracil [21]. The difference between the
kinetic profiles between PHB and PLGA micros-
pheres is that the copolymer microspheres have the
third kinetic range when at the final stage the abrupt
emission of 5-fluorouracil comes about. Most
recently, in our works describing release profiles of
DPD [15], indomethacin [15], and 5-nitrofurfurili-
den semicarbozone [22] from the films of PHB, we
have shown that for all three drugs the kinetic
curves of release have the initial diffusion stage
which smoothly transforms to the linear stage.
However, the third abrupt stage was absent for all
systems for several weeks. Taking into account
generally the Sipman’s three-stage model of release
[21, 23, 24], we note that for the PHB microspheres
having a higher hydrolysis resistance as compared
with PLGA, final stage of PHB network degrada-
tion and, hence, at the given conditions in vitro a
drastic DPD discharge has not attained (see Fig-
ure 2). At the same time, reposing on the literature
data and our experiments obtained for the ‘PHB
films – drug’ systems [15, 22] we assume that the
linear part of the kinetic curves for both the films
and the microspheres could be interpreted rather as
the start of zero-order hydrolytic reaction for PHB
macromolecules.
Diffusion-kinetic equation describing both linear
(hydrolysis) and nonlinear (diffusion) stages of the
DPD release profiles from the spherical subjects
could be written down as the sum of two terms :
desorption from the homogeneous sphere in accor-
dance with diffusion mechanism (the first sum-
mand involving square brackets in Equation (1a))
and the zero-power release (the addend in this
equation):
(1a)
Here D is the constant (or averaged) diffusion coef-
ficient of the drug in the polymer microspheres,
[cm2/sec]; Gt(z,t), ∂Gt/∂z, ∂Gt/∂t and ∂2Gt/∂z2 are
the current drug concentration [%], the first and
second derivatives of Gt with respect to t (time) or z
(spherical coordinate of diffusion) respectively;
and k is the zero-order constant. Following Crank
[25], transformation of Equation (1a) into the con-
ventional diffusion equation (1b) for spheres has
been performed by introduction of new variables
Ct ≡ Gt– kt and u = Ct·z:
(1b)
The boundary and initial conditions for solution of
differential Equation (1a) have been written by
standard way. At t = 0, C0 = const in the interval
0<z < R, and at t > 0 and z = R we have C0 = 0, at
t > 0 and z = 0, u = Ct·z =0 .
In accordance with our approach, at any time of
release the balance of the drug masses in the sur-
rounding medium is fulfilled as Equation (2):
Gmt = Mt + MHt (2)
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Figure 2. Kinetics profiles of DPD release from PHB
microspheres in vitro (phosphate buffer, 37°C).
A: General view of kinetic curves for the
microspheres with different diameters: 4(1),
19(2), 63(3), and 92(4) µm. The lines show the
second stage of release following the zero-order
equation. B: Details of the curves for the micros-
pheres with the smaller diameters: 4(1), 19(2)
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uhere Gmt is the total amount of DPD [mg] released
from the microspheres by the time t; Mt is the por-
tion of DPD mass released via the diffusion
process; and MHt is the other portion of DPD mass
released via degradation mechanism.
It is common knowledge that solution of Equa-
tion (1b) has two variations, namely for relatively
small time of diffusion when Mt/Μ∞ ≤ 0.5 approxi-
mately and for relatively long time when the condi-
tion Mt/Μ∞ > 0.5 is fulfilled. In the first instance
the approximation (3) is correct [25]:
(3)
where Mt, Μ∞ are cumulative weights of the drug
desorbed via diffusion by the time t and infinite
time (t→∞); respectively; R is averaged radius of
microsphere ; the other symbols are the same as in
Equation (1a). In the second instance the expres-
sion (4) should be used:
(4)
The graphic constructions of the diffusion data in
the framework of Equation (3) (Mt/Μ∞ – t0.5) or
logarithmic variant of Equation (4) (ln(Mt/Μ∞)–t)
enable us to use these equations as a criterion of
transport mechanism and simultaneously calculate
the DPD diffusivities in PHB. In Figure 3a the frag-
ments of kinetic profiles for release from PHB
microspheres with different diameters are shown.
The release data being plotted in coordinates of
Equation (3) – the relative loss of DPD in micros-
pheres (Mt/Μ ∞) versus square root of time –
give the values of diffusion coefficients, Dα =
π2R2·(tgα)2/36), where tgα is the slope ratio of lin-
ear part of the release curves. The examples of the
graphical solution for Equation (4) in semilog coor-
dinates for the microspheres with different diame-
ters are presented in Figure 3b. The integral diffu-
sion coefficients of DPD (Dβ) could be easily esti-
mated through expression Dβ=t g α·R2/π2, where
tgβ is also the slope ratio of linear part for the
release curves presented, however, in the semilog
linear coordinates (Figure 3b). Both diffusivities
(Dα, Dβ) are shown in Table 2. In case of molecular
diffusion one would expect a coincidence between
values of diffusion coefficients calculated by dif-
ferent Equations (3) and (4). Table 2 demonstrates
actually the closely adjacent values of DPD diffu-
sivities that support the real diffusion mechanism
of release going on the initial stage of the kinetics
curves. Just as in the paper [21], for the systems
PLGA loaded by 5-fluorocyle, in the PHB-DPD
samples concerned the diffusion coefficients
depend sharply on the size of the microspheres.
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Table 2. DPD diffusion coefficients in the PHB micros-
pheres for relatively small (Equation (3)) and long
(Equation (4)) time of diffusion
Diameter of
specimen 
·103 [cm]
Diffusion coefficient
·1011 [cm2/s] 
(Equation (4))
Diffusion coefficient
·1011 [cm2/s] 
(Equation (3))
0,36 00,10 00,08
1,90 01,5 02,0
6,30 02,8 02,6
9,20 21,1 16
Figure 3. Initial (a) and final (b) regions of diffusion stage for DPD release from the PHB microspheres with diameters
4 µm (1), 19 µm (2), 63 µm (3), and 92 µm (4). The data are represented in coordinates of Equation (3) and in
semilogarithmic coordinates of Equation (4)As previously stated above, the linear kinetics of
DPD release occurs together with diffusion mecha-
nism (see Figure 2). For the series of microparticles
with diameters 92, 63, and 19 µm the kinetic impact
comes into particular prominence after terminating
diffusion. In contrast to the diffusivity dependence
on microsphere size, the constant characteristics (k)
of linearity are scarcely affected by diameter of
PHB microparticles. The proper rate of hydrolytic
degradation should not dependent on geometry of a
sample as evidenced by Figure 2 (linear ranges for
microspheres with diameters are 92 and 63 µm).
The analogous conclusion has been published in
the basic paper of Witt and Kissel [26] for PLGA
microspheres.
The view of the kinetic profiles as well as the low
rate of DPD release are in satisfactory agreement
with kinetics of weight loss measured in vitro for
the PHB films. The thickness of the PHB films
(40 µm) was close to the diameters of our micros-
pheres. In this case we assume that the proper
hydrolysis kinetics may be similar for both the
microspheres and the films.
As is obvious from Figure 4, the change in weight
of the films as function of time occurs in accor-
dance with a zero-order equation as well. The
exception is an abrupt initial step of weight loss
which may be interpreted as a fast extraction of
residual impurities. Nature of these impurities is
still unknown. It is not impossible that the impuri-
ties include the traces of monomers and oligomers
coming during PHB isolation and film preparation.
Whatever the nature of impurities may be, the fol-
lowing slow loss in PHB weight is observed in the
same time frame that the linear kinetics of release
(compare Figures 2 and 4). Here we note again that
the slope of the kinetic curves reflected the weight
loss approximately identical. Taking into account
the above results, we may suppose that the domina-
tion of degradation for both PHB films and micros-
pheres is responsible for the second linear stage of
DPD release profiles. Assessment of the changes in
the weight of the PHB microspheres immediately
and the nature of this phenomenon are an urgent
experimental challenge.
4. Conclusions
We produced the biodegradable PHB-based micros-
pheres by the oil-in-water emulsion technique. The
microspheres with different diameters in interval
4–92 µm were loaded with DPD which presents the
class of inhibitors of cell proliferation and simulta-
neously the antithrombotic drugs. The kinetic pro-
files of drug release from microspheres into
phosphate buffer conformed to the superposition of
diffusion and zero-order process of PHB degrada-
tion. A sufficiently protensive linear part of kinetic
profiles provides a way for application the PHB-
DPD microsystem as a local drug release medical
preparation.
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